Pluri Inc., a biotechnology company established in 2001 and headquartered in Haifa, Israel, specializes in developing innovative placenta-derived cell therapies. Its core mission is to tackle a range of inflammatory conditions, muscle injuries, and hematological disorders. The company's therapeutic pipeline centers on placental expanded (PLX) cell technology. A key candidate, PLX-PAD, is in advanced clinical development, with ongoing Phase III trials for muscle recovery after hip fracture surgery, Phase II studies for acute respiratory distress syndrome associated with COVID-19, and Phase I/II trials for steroid-refractory Graft-versus-Host Disease. Additionally, Pluri is advancing PLX-R18, a treatment designed to aid in incomplete hematopoietic recovery following hematopoietic cell transplantation and to address acute radiation syndrome. The company rebranded to Pluri Inc. in July 2022, having previously operated as Pluristem Therapeutics Inc.
Previous close
$0.94
−$0.0298 · -3.07%
Regular session · ET · Market data may be delayed.
Pluri Inc., a biotechnology company established in 2001 and headquartered in Haifa, Israel, specializes in developing innovative placenta-derived cell therapies. Its core mission is to tackle a range of inflammatory conditions, muscle injuries, and hematological disorders. The company's therapeutic pipeline centers on placental expanded (PLX) cell technology. A key candidate, PLX-PAD, is in advanced clinical development, with ongoing Phase III trials for muscle recovery after hip fracture surgery, Phase II studies for acute respiratory distress syndrome associated with COVID-19, and Phase I/II trials for steroid-refractory Graft-versus-Host Disease. Additionally, Pluri is advancing PLX-R18, a treatment designed to aid in incomplete hematopoietic recovery following hematopoietic cell transplantation and to address acute radiation syndrome. The company rebranded to Pluri Inc. in July 2022, having previously operated as Pluristem Therapeutics Inc.
Day range
Current $0.94
52-week range
Current $0.94
Regular session · ET · Market data may be delayed.
GoAI Score
Sell
Valuation
36
Expensive
Sentiment
50
Mixed
Risk
71
High Risk
Momentum
29
Weakening
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
Pluri Inc., a biotechnology company established in 2001 and headquartered in Haifa, Israel, specializes in developing innovative placenta-derived cell therapies. Its core mission is to tackle a range of inflammatory conditions, muscle injuries, and hematological disorders. The company's therapeutic pipeline centers on placental expanded (PLX) cell technology. A key candidate, PLX-PAD, is in advanced clinical development, with ongoing Phase III trials for muscle recovery after hip fracture surgery, Phase II studies for acute respiratory distress syndrome associated with COVID-19, and Phase I/II trials for steroid-refractory Graft-versus-Host Disease. Additionally, Pluri is advancing PLX-R18, a treatment designed to aid in incomplete hematopoietic recovery following hematopoietic cell transplantation and to address acute radiation syndrome. The company rebranded to Pluri Inc. in July 2022, having previously operated as Pluristem Therapeutics Inc.
Day range
Current $0.94
52-week range
Current $0.94
Recent quarterly results
Recent quarterly results
Third-party consensus; not a GoAI recommendation.
Average target
$12.00
1176.60% upside| Action | Effective date | Details | Record date | Payment date |
|---|---|---|---|---|
Stock split | Apr 1, 2024 | 1:8 | — | — |
Stock split | Jul 25, 2019 | 1:10 | — | — |
Stock split | Nov 26, 2007 | 1:200 | — | — |
Effective Apr 1, 2024
1:8
Effective Jul 25, 2019
1:10
Effective Nov 26, 2007
1:200
AI-generated and delayed market data for informational and educational purposes only. Not investment advice.